Last checked at 31 May 2019 07:00
31 May 2019
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
Board Transition
Alison Kibble steps down from OBD Board after 11 years' service
Further to the announcement of 11 January 2019, Oxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, today announces that Alison Kibble has today stepped down from the Board as Non-Executive Director.
Alison first joined OBD's Board in December 2007 as a representative of the University of Oxford and since the Company's IPO has served as Chair of the Audit Committee and as a member of the Nomination and Remuneration Committees.
Following Alison's stepping down, membership of the sub-committees of the Board is as follows:
Sub-committee | Chair | Other members |
Audit committee | David Holbrook | Peter Pack |
Nomination committee | Stephen Diggle | David HolbrookChristian Hoyer Millar |
Remuneration committee | Peter Pack | David Holbrook |
Christian Hoyer Millar, Chief Executive Officer of Oxford BioDynamics, said:
"On behalf of the Board I would like to thank Alison for her many years of service to OBD. It has been a pleasure to work with her since the Company was spun out of the University of Oxford in 2007. Alison has offered the Executive Directors consistent support and challenge throughout her tenure as a Non-Executive Director, benefiting the Company and its shareholders. We will miss her, and wish her every future success."
Alison Kibble added:
"It has been a real privilege to be part of the team that has seen OBD grow from a small company into a successful listed entity with world-class technology and partnerships with major pharma and institutions. I wish the Board and all the employees well as they take the Company forward into the next exciting phase."
-ENDS-
For further details please contact:
Oxford BioDynamics Plc Christian Hoyer Millar, CEO Paul Stockdale, CFO | +44 (0)1865 518910 |
Shore Capital Nominated Advisor and Broker Stephane Auton Edward Mansfield |
+44 (0)20 7408 4090 |
FTI Consulting Financial Public Relations Adviser Brett Pollard Natalie Garland-Collins |
+44 (0)20 3727 1000 |
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.
Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.